Quinoline carboxylic acid
    1.
    发明授权
    Quinoline carboxylic acid 失效
    喹啉羧酸

    公开(公告)号:US5859026A

    公开(公告)日:1999-01-12

    申请号:US860469

    申请日:1997-07-09

    CPC分类号: C07D401/04

    摘要: 5-Amino-7-((3S,4S)-3-amino-4-methyl (or ethyl)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid or a pharmacologically acceptable salt thereof represented by the following formula wherein asymmetric carbon atoms marked with asterisks are in the S-configurations and R.sup.1 represents methyl group or ethyl group; and an antibacterial agent comprising said compound as an active ingredient. ##STR1##

    摘要翻译: PCT No.PCT / JP95 / 02614 Sec。 371日期1997年7月9日第 102(e)日期1997年7月9日PCT 1995年12月20日PCT PCT。 公开号WO96 / 22988 日期:19965年9月1日 - 氨基-7 - ((3S,4S)-3-氨基-4-甲基(或乙基)-1-吡咯烷基)-1-环丙基-6-氟-1,4-二氢-8 - 甲基-4-氧代喹啉-3-羧酸或其药理学上可接受的盐,其中标有星号的不对称碳原子为S-构型,R1表示甲基或乙基; 以及包含所述化合物作为活性成分的抗菌剂。

    5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
    2.
    发明授权
    5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative 失效
    5-氨基-8-甲基-7-吡咯烷基喹啉-3-羧酸衍生物

    公开(公告)号:US5547962A

    公开(公告)日:1996-08-20

    申请号:US261446

    申请日:1994-06-17

    CPC分类号: C07D215/56 C07D401/04

    摘要: A 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative represented by the general formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a halogenated lower alkanoyl group or a residue of carboxylic acid ester; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 or R.sup.6 are each independently a hydrogen atom or a lower alkyl group; or two of R.sup.4, R.sup.5 and R.sup.6 may be taken together to form a --(CH.sub.2).sub.n -group wherein n is 1 or 2, a stereoisomer thereof, or a pharmacologically acceptable salt thereof, the process for preparing these compounds, a pharmaceutical composition comprising an effective amount of these compounds and methods for the treatment of infectious diseases through the administration to patients of an effective amount of these compounds, and intermediates of these compounds are disclosed. These compounds are effective as antibacterial agents.

    摘要翻译: 由以下通式表示的5-氨基-8-甲基-7-吡咯烷基喹啉-3-羧酸衍生物:其中R1是氢原子或低级烷基; R2是氢原子,低级烷基,低级烷酰基,卤代低级烷酰基或羧酸酯的残基; R3是氢原子或低级烷基; R4,R5或R6各自独立地为氢原子或低级烷基; 或R 2,R 5和R 6中的两个可以一起形成其中n为1或2的 - (CH 2)n - 基团,其立体异构体或其药理学上可接受的盐,制备这些化合物的方法,药物组合物 包括有效量的这些化合物和通过向患者施用有效量的这些化合物来治疗感染性疾病的方法,以及这些化合物的中间体。 这些化合物作为抗菌剂是有效的。

    Crystal of hydrate and process for preparation thereof
    3.
    发明授权
    Crystal of hydrate and process for preparation thereof 失效
    水合物晶体及其制备方法

    公开(公告)号:US6075035A

    公开(公告)日:2000-06-13

    申请号:US11752

    申请日:1998-02-23

    CPC分类号: C07D491/04

    摘要: Dihydrate crystal of 3-[4-(8-fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidino]propionic acid providing high-intensity diffraction peaks at diffraction angles (2.theta.) of about 4.2.degree., 17.0.degree., and 21.3.degree. in a powder X-ray diffraction profile; a medicament comprising the dihydrate crystal; and a process for preparing the dihydrate crystal which comprises the steps of treating a crystalline substance containing an anhydride crystal of the above compound with hydrous acetone, and subjecting the product to drying treatment and moistening treatment.

    摘要翻译: PCT No.PCT / JP96 / 02352 Sec。 371日期1998年2月23日 102(e)1998年2月23日PCT PCT 1996年8月23日PCT公布。 出版物WO97 / 09330 日期1997年3月13日提供高强度衍射峰的3- [4-(8-氟-5,11-二氢苯并[b]氧杂环庚烯并[4,3-b]吡啶-11-亚基)哌啶子基]丙酸的二水合晶体 在衍射角(2θ)为约4.2°,17.0°和21.3°的粉末X射线衍射图中; 包含二水合物晶体的药物; 以及制备二水合物晶体的方法,包括以下步骤:用含水丙酮处理含有上述化合物的无水物结晶的结晶物质,并对产物进行干燥处理和润湿处理。

    Benzamide derivative
    4.
    发明授权
    Benzamide derivative 失效
    苯甲酰胺衍生物

    公开(公告)号:US5500422A

    公开(公告)日:1996-03-19

    申请号:US348808

    申请日:1994-11-28

    摘要: A benzamide derivative represented by the following formula: ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkanoyl group; R.sup.2 represents a hydrogen atom or a halogen atom; R.sup.3 represents a lower alkoxy group; R.sup.4 represents a hydrogen atom or a lower alkyl group; R.sup.5 represents a hydrogen atom, a lower alkyl group, or a lower alkoxy group; A represents C.sub.1 -C.sub.7 alkylene group which may optionally be substituted with a lower alkyl group; X represents a methylene group, an oxygen atom, or a sulfur atom; m represents an integer of from 0 to 3; n represents an integer of from 0 to 3; and p represents an integer of from 0 to 2 and a pharmacologically acceptable salt thereof is provided. These compounds are useful since they have gastrointestinal stimulating activity, and a pharmaceutical composition comprising said compound is useful for the treatment of gastrointestinal diseases.

    摘要翻译: 由下式表示的苯甲酰胺衍生物:其中R 1表示氢原子或低级烷酰基; R2表示氢原子或卤素原子; R3表示低级烷氧基; R4代表氢原子或低级烷基; R5表示氢原子,低级烷基或低级烷氧基; A表示可以被低级烷基取代的C1-C7亚烷基; X表示亚甲基,氧原子或硫原子; m表示0〜3的整数, n表示0〜3的整数, p表示0〜2的整数,并且其药理学上可接受的盐。 这些化合物是有用的,因为它们具有胃肠道刺激活性,并且包含所述化合物的药物组合物可用于治疗胃肠道疾病。

    Benzamide derivatives
    6.
    发明授权
    Benzamide derivatives 失效
    苯甲酰胺衍生物

    公开(公告)号:US5395832A

    公开(公告)日:1995-03-07

    申请号:US104095

    申请日:1993-08-11

    摘要: A benzamide derivative represented by the following formula: ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkanoyl group; R.sup.2 represents a hydrogen atom or a halogen atom; R.sup.3 represents a lower alkoxy group; R.sup.4 represents a hydrogen atom or a lower alkyl group; R.sup.5 represents a hydrogen atom, a lower alkyl group, or a lower alkoxy group; A represents C.sub.1 -C.sub.7 alkylene group which may optionally be substituted with a lower alkyl group; X represents a methylene group, an oxygen atom, or a sulfur atom; m represents an integer of from 0 to 3; n represents an integer of from 0 to 3; and p represents an integer of from 0 to 2 and a pharmacologically acceptable salt thereof is provided. These compounds are useful since they have gastrointestinal stimulating activity, and a pharmaceutical composition comprising said compound is useful for the treatment of gastrointestinal diseases.

    摘要翻译: PCT No.PCT / JP92 / 00134 Sec。 371日期:1993年8月11日 102(e)日期1993年8月11日PCT提交1992年2月12日PCT公布。 公开号WO92 / 14705 日本9月3日,1992。一种苯甲酰胺衍生物,由下式表示:其中R1表示氢原子或低级烷酰基; R2表示氢原子或卤素原子; R3表示低级烷氧基; R4代表氢原子或低级烷基; R5表示氢原子,低级烷基或低级烷氧基; A表示可以被低级烷基取代的C1-C7亚烷基; X表示亚甲基,氧原子或硫原子; m表示0〜3的整数, n表示0〜3的整数, p表示0〜2的整数,并且其药理学上可接受的盐。 这些化合物是有用的,因为它们具有胃肠道刺激活性,并且包含所述化合物的药物组合物可用于治疗胃肠道疾病。

    Benzenesulfonamide derivatives and use thereof
    7.
    发明授权
    Benzenesulfonamide derivatives and use thereof 失效
    苯磺酰胺衍生物及其用途

    公开(公告)号:US5597848A

    公开(公告)日:1997-01-28

    申请号:US397068

    申请日:1995-03-16

    CPC分类号: C07C311/29 C07C311/19

    摘要: A benzenesulfonamide derivative represented by the following general formula: ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group or a halogen atom; R.sup.2 represents a C.sub.1 -C.sub.10 straight- or branched-chain alkyl group, a C.sub.3 -C.sub.8 cycloalkyl group which may be substituted with one or more C.sub.1 -C.sub.6 alkyl groups on its ring, a C.sub.1 -C.sub.6 alkyl group substituted with one or more C.sub.3 -C.sub.8 cycloalkyl groups, 1-adamantylmethyl group, 2-norbornylmethyl group, or a C.sub.1 -C.sub.6 alkyl group substituted with one or more phenyl groups whose benzene ring may have one or more substituents; R.sup.3 represents a hydrogen atom or a lower alkyl group; and n is an integer of from 2 to 4, and a pharmacologically acceptable salt thereof. The present compounds have thromboxane A.sub.2 antagonistic activity, leucotriene antagonistic activity and the like and useful as a platelet aggregation inhibitor, antithrombotic agent, antiasthmatic agent and antiallergic agent.

    摘要翻译: PCT No.PCT / JP93 / 01382 Sec。 371日期1995年3月16日 102(e)1995年3月16日PCT PCT 1993年9月29日PCT公布。 公开号WO94 / 07848 日本1994年4月14日由以下通式表示的苯磺酰胺衍生物:其中R 1表示氢原子,低级烷基,低级烷氧基或卤素原子; R2表示C1-C10直链或支链烷基,可以在其环上被一个或多个C 1 -C 6烷基取代的C 3 -C 8环烷基,被一个或多个C 3取代的C 1 -C 6烷基 -C8环烷基,1-金刚烷基甲基,2-降冰片基甲基或被苯环可以具有一个或多个取代基的一个或多个苯基取代的C 1 -C 6烷基; R3表示氢原子或低级烷基; n为2〜4的整数,及其药理学上可接受的盐。 本发明化合物具有血栓素A2拮抗活性,白三烯拮抗活性等,可用作血小板聚集抑制剂,抗血栓形成剂,止喘剂和抗过敏剂。

    Photostable aqueous solution comprising benzyl alcohol derivatives
    9.
    发明授权
    Photostable aqueous solution comprising benzyl alcohol derivatives 有权
    包含苯甲醇衍生物的光稳定水溶液

    公开(公告)号:US6162833A

    公开(公告)日:2000-12-19

    申请号:US292664

    申请日:1999-04-16

    摘要: Aqueous solution, including at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol represented by the following formula: ##STR1## and pharmacologically acceptable salt thereof. The aqueous solution also includes at least one photostabilizer selected from the group consisting of saccharide, sugar alcohol, and polyalcohol. A content of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof is 0.01 to 10% (w/v) based on a volume of the aqueous solution. A content of the at least one photostabilizer is 1 to 50% (w/v) based on the volume of the aqueous solution. The content of the at least one photostabilizer is at least 10% (w/w) based on a total weight of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof. Method of making a stabilized aqueous solution.

    摘要翻译: 水溶液,包括由下式表示的光学活性( - ) - (R)-α-((叔丁基氨基)甲基)-2-氯-4-羟基苄醇中的至少一种:及其药理学上可接受的盐。 水溶液还包括至少一种选自糖,糖醇和多元醇的光稳定剂。 光学活性( - ) - (R)-α-((叔丁基氨基)甲基)-2-氯-4-羟基苄醇及其药学上可接受的盐中的至少一种的含量为0.01〜10%(w / v)基于一定体积的水溶液。 基于水溶液的体积,至少一种光稳定剂的含量为1至50%(w / v)。 至少一种光稳定剂的含量基于光学活性( - ) - (R)-α-((叔丁基氨基)甲基) - 2-氯-4-羟基苄醇及其药理学上可接受的盐。 制备稳定水溶液的方法